Fluminorex is a centrally acting sympathomimetic which is related to other drugs such as aminorex and pemoline. It was developed as an appetite suppressant by McNeil Laboratories in the 1950s.[1][2]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H9F3N2O |
Molar mass | 230.190 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Synthesis
edit2-amino-1-[4-(trifluoromethyl)phenyl]ethanol [776-02-3] (1) cyanogen bromide [506-68-3] (2)
See also
editReferences
edit- ^ US Patent 3278382 - 2-amino-5-aryloxazoline compositions and methods of using same
- ^ Maier J, Mayer FP, Brandt SD, Sitte HH (October 2018). "DARK Classics in Chemical Neuroscience: Aminorex Analogues". ACS Chemical Neuroscience. 9 (10): 2484–2502. doi:10.1021/acschemneuro.8b00415. PMC 6287711. PMID 30269490.
- ^ Poos, G. I., Carson, J. R., Rosenau, J. D., Roszkowski, A. P., Kelley, N. M., McGowin, J. (May 1963). "2-amino-5-Aryl-2-oxazolines. Potent New Anorectic Agents". Journal of Medicinal Chemistry. 6 (3): 266–272. doi:10.1021/jm00339a011. PMID 14185981.
- ^ Poos George Ireland, U.S. patent 3,278,382 (1966 to Janssen Pharmaceuticals Inc).